The global smart pills market size was valued at USD 1.71 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.3% from 2024 to 2030. Smart pills, often called digital pills or ingestible sensors, represent a breakthrough in medical technology by combining pharmaceuticals with digital monitoring proficiencies. These pills are implanted with tiny sensors that transfer data of the body's response to medication ingestion, such as vital signs or medication adherence, to devices such as smartphones or computers. By issuing real-time insights into patient health and treatment effectiveness, smart pills enable healthcare professionals to align treatment plans more precisely and intervene promptly when there is a need.

Other significant growth aspects for the smart pill technologies market are attractive reimbursement circumstances, patient demand for less invasive treatments, technical improvements in endoscopic techniques, and the growing prevalence of colon cancer. In addition, the benefits of smart pill technology, such as breakthroughs in endoscopic procedures, focused medicine administration, and simple remote patient monitoring, boost the sale of smart pill technologies.

Gather more insights about the market drivers, restrains and growth of the Smart Pills Market

Detailed Segmentation:

Application Insights

Capsule endoscopy dominated the market and accounted for the largest revenue share of 54.1% attributed to the painless procedure of diagnosing gastrointestinal disorders. In this technique, the patient has to swallow a large vitamin pill-sized capsule that is wireless and compact with small cameras and sensors that assist in detection and tracking purposes. Hence, the procedure causes minimal discomfort and is painless, with a quick recovery. The advantages of smart pills, detailed health observation of different physiological metrics, and an accurate diagnosis result in the market expansion of smart drugs

Disease Indication Insights

Celiac disease led the market and accounted for the largest revenue share 2023 driven by the increasing prevalence of gastrointestinal disorders and chronic diseases, such as cancer and diabetes, which necessitate innovative diagnostic and treatment solutions. In addition, the rising geriatric population and the demand for minimally invasive procedures enhance the appeal of smart pills. Furthermore, technological advancements in drug delivery systems and the integration of advanced sensors further contribute to market expansion, making smart pills a vital tool in modern healthcare.

Target Area Insights

Small intestine dominated the market and held the largest revenue share in 2023 driven by the rising incidence of small intestine disorders, such as Crohn's and celiac diseases. The increasing demand for noninvasive diagnostic tools and advancements in capsule endoscopy technology further enhance market potential. Furthermore, the intricate anatomy of the small intestine presents challenges for traditional diagnostic methods, making smart pills an attractive alternative. These factors collectively contribute to smart pills' expanding application and acceptance in gastrointestinal healthcare.

End-use Insights

Outpatient facilities dominated the market with a share of 53.3% in 2023 owing to the rising demand for appropriate medicines and initiatives by governments to promote automated medication technologies in healthcare to minimize errors and risks. This results in significant popularity, mainly for outpatient facilities and intense care for lower-risk patients.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global lung adenocarcinoma treatment market size was estimated at USD 5.51 billion in 2023 and is projected to grow at a CAGR of 10.68% from 2024 to 2030.

• The global hairy cell leukemia treatment market size is estimated at USD 102.1 million in 2023 and is expected to grow at a CAGR of 5.4% from 2024 to 2030.

Key Companies & Market Share Insights

Some of the key companies in the smart pills market include Medtronic, Otsuka Holdings Co., Ltd., Olympus Corporation, CapsoCam Plus, Pentax Medical, JINSHAN Science & Technology (Group) Co., Ltd., Check-Cap Ltd. in the market are focusing on development & to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

• Medtronic offers an innovative PillCam technology. This ingestible capsule enables non-invasive imaging of the gastrointestinal tract, particularly the colon, aiding in the diagnosis of disorders such as colorectal cancer.
• Olympus focuses on developing advanced imaging technologies, including its capsule endoscopes. These smart pills are designed to provide high-quality visual data from the gastrointestinal tract, facilitating the early detection of diseases.

Key Smart Pills Companies:

The following are the leading companies in the smart pills market. These companies collectively hold the largest market share and dictate industry trends.

• Medtronic 
• Otsuka Holdings Co., Ltd.
• Olympus Corporation
• CapsoCam Plus
• Pentax Medical
• JINSHAN Science & Technology (Group) Co., Ltd. 
• Check-Cap Ltd. 
• etectRx
• INTROMEDIC 
• Shenzen Jifu Medical Technology Co., Ltd
• BodyCapUSA

Smart Pills Market Segmentation

Grand View Research has segmented the global smart pills market report based on application, and region:

Smart Pills Application Outlook (Revenue, USD Million, 2018 - 2030)

• Product
  • Capsule Endoscopy
  • Drug Delivery
• Tools
• Patient Monitoring System

Smart Pills Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Order a free sample PDF of the Smart Pills Market Intelligence Study, published by Grand View Research.

Recent Developments

• In April 2024, PENTAX Medical EMEA launched an innovative Digital Capture Module 9380 to transform medical recording competencies in ENT and speech-language pathology settings. This compact and portable device offers advanced and customizable recording features, addressing the evolving needs of healthcare professionals. The 9380 sets a new benchmark in medical imaging technology through its multi-camera source video recording, seamless recording and playback functionalities, and an intuitive software interface. The module's flexibility and customization options cater to the unique requirements of individual facilities, making it a universal solution for various applications, including stroboscopy, endoscopy, FEES, and VFSS.